Systematic Review: The Safety and Efficacy of Growth Hormone in the Healthy Elderly
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Human growth hormone (GH) is widely used as an antiaging therapy, although its use for this purpose has not been approved by the U.S. Food and Drug Administration and its distribution as an antiaging agent is illegal in the United States. PURPOSE: To evaluate the safety and efficacy of GH therapy in the healthy elderly. DATA SOURCES: The authors searched MEDLINE and EMBASE databases for English-language studies published through 21 November 2005 by using such terms as growth hormone and aging. STUDY SELECTION: The authors included randomized, controlled trials that compared GH therapy with no GH therapy or GH and lifestyle interventions (exercise with or without diet) with lifestyle interventions alone. Included trials provided GH for 2 weeks or more to community-dwelling participants with a mean age of 50 years or more and a body mass index of 35 kg/m2 or less. The authors excluded studies that evaluated GH as treatment for a specific illness. DATA EXTRACTION: Two authors independently reviewed articles and abstracted data. DATA SYNTHESIS: 31 articles describing 18 unique study populations met the inclusion criteria. A total of 220 participants who received GH (107 person-years) completed their respective studies. Study participants were elderly (mean age, 69 years [SD, 6]) and overweight (mean body mass index, 28 kg/m2 [SD, 2]). Initial daily GH dose (mean, 14 microg per kg of body weight [SD, 7]) and treatment duration (mean, 27 weeks [SD, 16]) varied. In participants treated with GH compared with those not treated with GH, overall fat mass decreased (change in fat mass, -2.1 kg [95% CI, -2.8 to -1.35] and overall lean body mass increased (change in lean body mass, 2.1 kg [CI, 1.3 to 2.9]) (P < 0.001), and their weight did not change significantly (change in weight, 0.1 kg [CI, -0.7 to 0.8]; P = 0.87). Total cholesterol levels decreased (change in cholesterol, -0.29 mmol/L [-11.21 mg/dL]; P = 0.006), although not significantly after adjustment for body composition changes. Other outcomes, including bone density and other serum lipid levels, did not change. Persons treated with GH were significantly more likely to experience soft tissue edema, arthralgias, carpal tunnel syndrome, and gynecomastia and were somewhat more likely to experience the onset of diabetes mellitus and impaired fasting glucose. LIMITATIONS: Some important outcomes were infrequently or heterogeneously measured and could not be synthesized. Most included studies had small sample sizes. CONCLUSIONS: The literature published on randomized, controlled trials evaluating GH therapy in the healthy elderly is limited but suggests that it is associated with small changes in body composition and increased rates of adverse events. On the basis of this evidence, GH cannot be recommended as an antiaging therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, no overall change was noted in bodyweight comparing treated participants with those taking placebo or doing exercise.”
From Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases (2014) · cites this paper as [96]
In the citing paper
“A systematic review noted that individuals treated with GH had a significant decrease in fat mass (−2·08 kg, 95% CI −1·35 to −2·80 kg) and a significant increase in lean body mass (+2·13 kg, 95% CI 1·32 to 2·94 kg).”
From Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases (2014) · cites this paper as [96]
In the citing paper
“Participants who received GH therapy were also more likely to have side-effects including soft tissue oedema, arthralgias, carpal tunnel syndrome, and gynaecomastia, and to develop fasting hyperglycaemia or diabetes,96”
From Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases (2014) · cites this paper as [96]
In the citing paper
“Many studies reported only marginal effects of growth hormone (GH) supplementation on skeletal muscle mass, bone density, fat mass and physical function [116].”
From Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review (2019) · cites this paper as [116]
In the citing paper
“Moreover, the majority of trials conducted on GH supplementation have reported a high incidence of adverse effects [116, 118, 119].”
From Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review (2019) · cites this paper as [116]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“We report those summary results for which the I(2) statistic was greater than 50% (reflecting substantial heterogeneity) (33).”
BackgroundThe Handbook of Research Synthesis.
Howel, D., Cooper, H., & Hedges, L. V. (1995) · Biometrics · doi:10.2307/2533295 · Cited by 3,642
Verhagen, A. P., de Vet, H. C. W., de Bie, R. A., Kessels, A. G. H., Boers, M., Bouter, L. M., & Knipschild, P. G. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00131-0 · Cited by 2,379 · cited 1×
“We abstracted 4 types of data from each study: 1) study quality (for example, quality of randomization, blinding, outcomes, and statistical analyses) (29, 30); 2) study sample characteristics (for example, age, sex, weight, medical conditions, and baseline IGF-1 levels); 3) study interventions (for example, dosage, fr…”
MethodPlasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998) · Science · doi:10.1126/science.279.5350.563 · Cited by 1,996
Effects of Human Growth Hormone in Men over 60 Years Old
Rudman, D., Feller, A. G., Nagraj, H. S., Gergans, G. A., Lalitha, P. Y., Goldberg, A. F., Schlenker, R. A., Cohn, L., Rudman, I. W., & Mattson, D. E. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007053230101 · Cited by 1,555
Systems to rate the strength of scientific evidence.
West, S. L., King, V., Carey, T. S., Lohr, K. N., Mckoy, N. A., Sutton, S. F., & Lux, L. J. (2002) · PubMed · Cited by 923
Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review
Carroll, P. V., Christ the members of Growth Hormon, E. R., Bengtsson, B. Å., Carlsson, L., Christiansen, J. S., Clemmons, D., Hintz, R., Ho, K., Laron, Z., Sizonenko, P., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4594 · Cited by 822
Treatment of adults with growth hormone (GH) deficiency with recombinant human GH.
Bengtsson, B. A., Edén, S., Lönn, L., Kvist, H., Stokland, A., Lindstedt, G., Bosaeus, I., Tölli, J., Sjöström, L., & Isaksson, O. G. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.2.8432773 · Cited by 778 · cited 1×
“This fluid retention may be transient (79, 80) and may account for the smaller, however not significant, difference in lean body mass seen in long-term studies compared with short-term studies.”
ResultClinical Aspects of Growth Hormone Deficiency in Adults
BOER, H. D., BLOK, G.-J., & DER VEEN, E. A. V. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-63 · Cited by 723 · cited 1×
“Furthermore, some of the increase from GH in lean body mass may be due to fluid retention because methods evaluating lean body mass have difficulty differentiating lean solid tissue from fluid mass (78).”
BackgroundObesity as a cardiovascular risk factor
Sowers, J. R. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.012 · Cited by 584 · cited 1×
“Although GH use may decrease total cholesterol levels minimally, this effect did not remain robust in sensitivity analysis and may be related to changes in body composition (81, 82) rather than to an intrinsic effect on cholesterol metabolism.”
Background
Research works printed but not linked: 24
- Lamberts SW, 2000, Horm Res, 53, 42
- Hoffman AR, 1999, J Endocrinol Invest, 22, 4
- Savine R, 1999, J Endocrinol Invest, 22, 142
- Savine R, 2000, Horm Res, 53, 37
- Biller BM, 2000, J Clin Endocrinol Metab, 85, 970
- Lyle WG, 2002, Plast Reconstr Surg, 110, 1585
- 10.1210/jcem.87.2.8206 · doi:10.1210/jcem.87.2.8206 · Paper page
- 10.1210/jcem.86.8.7773 · DOI · Paper page
- Johannsson G, 1997, J Clin Endocrinol Metab, 82, 727
- Holloway L, 1994, J Clin Endocrinol Metab, 79, 470
- Thompson JL, 1998, J Clin Endocrinol Metab, 83, 1477
- Taaffe DR, 1996, J Clin Endocrinol Metab, 81, 421
- Yarasheski KE, 1995, Am J Physiol, 268, 268
- Taaffe DR, 1994, J Clin Endocrinol Metab, 79, 1361
- Viikari J, 1998, Duodecim, 114, 867
- Bierich JR, 1991, Z Gerontol, 24, 337
- Kozakowski J, 1998, Pol Arch Med Wewn, 100, 306
- Kann P, 1996, Med Klin (Munich), 91, 46
- Jørgensen JO, 1999, J Endocrinol Invest, 22, 150
- 10.1210/jcem.87.6.8542 · doi:10.1210/jcem.87.6.8542 · Paper page
- Bengtsson BA, 1993, J Clin Endocrinol Metab, 76, 309
- 10.1210/jcem.87.5.8454 · doi:10.1210/jcem.87.5.8454 · Paper page
- Johannsson G, 1996, Endocrinol Metab Clin North Am, 3, 3
- 10.1210/jcem.83.11.5223 · DOI · Paper page
Cited by
Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases
Kalyani, R. R., Corriere, M., & Ferrucci, L. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70034-8 · Cited by 1,102
Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects
Møller, N., & Jørgensen, J. O. L. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0027 · Cited by 1,039
Growth Hormone, Insulin-Like Growth Factors, and the Skeleton
Giustina, A., Mazziotti, G., & Canalis, E. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0036 · Cited by 914
“This finding may be influenced by the scarcity of controlled trials suitable for the meta-analysis, as well as by the heterogeneity of the subjects examined (401).”
BackgroundKim, D. H., & Rockwood, K. (2024) · New England Journal of Medicine · doi:10.1056/nejmra2301292 · Cited by 824
The GH/IGF-1 axis in ageing and longevity
Junnila, R. K., List, E. O., Berryman, D. E., Murrey, J. W., & Kopchick, J. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.67 · Cited by 574
Metadata
- Authors
- Liu, H., Bravata, D. M., Olkin, I., Nayak, S., Roberts, B., Garber, A. M., & Hoffman, A. R.
- Affiliations
- VA Palo Alto Health Care System (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2007-01-16
- Volume
- 146
- Issue
- 2
- Pages
- 104-115
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2044351326
- Cited by
- 370
- References
- 74
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 10 · 2023: 12 · 2022: 16 · 2021: 22 · 2020: 9 · 2019: 24 · 2018: 18 · 2017: 19 · 2016: 17 · 2015: 10 · 2014: 16 · 2013: 18 · 2012: 19
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Agency for Healthcare Research and Quality (HS000028-19)
- Genentech
- National Institute on Aging (AG 17253, P30AG017253)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Keywords
- growth hormone therapy, anti-aging therapy, healthy older adults, overweight adults, body composition, fat mass, lean body mass, cholesterol, bone mineral density, soft tissue edema, adverse effects, lifestyle intervention, diet and exercise, drug safety and efficacy, osteoporosis, osteoarthritis, avascular necrosis, cancer risk, cardiovascular risk
- MeSH terms
- Aged, Aging, Blood Glucose, Body Composition, Humans, Life Style, Lipids, Recombinant Proteins, Exercise, Bone Density, Human Growth Hormone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic Review: The Safety and Efficacy of Growth Hormone in the Healthy Elderly. https://app.cochat.ai/papers/10.7326/0003-4819-146-2-200701160-00005
- The paper
- Liu, H., Bravata, D. M., Olkin, I., Nayak, S., Roberts, B., Garber, A. M., & Hoffman, A. R. (2007). Systematic Review: The Safety and Efficacy of Growth Hormone in the Healthy Elderly. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-146-2-200701160-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.